The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee today recommended the approval of Johnson & Johnson’s COVID-19 vaccine candidate. The panel voted unanimously to recommend that FDA issue an emergency use authorization for the candidate, which is administered as a single dose.

Once FDA authorizes the candidate’s emergency use, Johnson & Johnson will turn doses over the Federal Emergency Management Agency’s contractor, McKesson, for shipment with administration kits. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is also scheduled to meet over the weekend to determine if limits should be placed on those who would receive the Johnson & Johnson vaccine.

AHA members will receive a Special Bulletin with details on the vaccine’s administration and storage, along with other important details, following FDA’s decision.

Related News Articles

Headline
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2…
Headline
The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s…
Blog
Our doctors, nurses and clinical staff have responded to the COVID-19 pandemic with dedication and bravery. Yet, the pandemic’s longevity, as well as COVID-19’…
Headline
The Centers for Medicare & Medicaid Services will no longer waive certain requirements for long-term care and skilled nursing facilities beginning May 9 or…
Chairperson's File
One legacy of our response to COVID-19 surely will be how it has accelerated the adoption of virtual care. It is one of the more encouraging developments…
Headline
Pfizer today said it is seeking an amended emergency use authorization for its COVID-19 vaccine, requesting that the Food and Drug Administration allow…